Boston Scientific

Rank: 13
2016 Rank16
R&D Spend:$920,000,000
Fiscal year ending:12-31-16
Click here to see all 100

Boston Scientific put its turnaround in the rear view mirror in 2016 and set its sights on accelerating and stabilizing that growth by expanding into high-growth adjacent markets.

“Our investment strategy has focused on diversifying our portfolio and shifting the growth profile of the company toward higher-growth markets and focusing on globalization,” a company spokeswoman told us, noting that once-core products likes stents, pacemakers and defibrillators are now only 50% of the total offering.

“We expect that to be about a third as we continue to grow with our robust pipeline,” she said, adding that nearly half of Boston Scientific’s sales come from global markets.

A June 2016 restructuring meant little net change to total employment numbers, as BSC looked to pare its pre-tax expenses by $115 million to $150 million by the end of 2020.

Big 100 Mini Logo Key Personnel: Michael Mahoney, chairman & CEO; Kevin Ballinger, EVP & president, interventional cardiology; Supratim Bose, EVP & president, Asia-Pacific, Middle East & Africa; Daniel Brennan, EVP & CFO; Art Butcher, SVP & president, endoscopy; Wendy Carruthers, SVP, HR; Joseph Fitzgerald, EVP & president, rhythm management; Edward Mackey, EVP, global operations; Dr. Ian Meredith, EVP & global CMO; Jeff Mirviss, SVP & president, peripheral interventions; Maulik Nanavaty, SVP & president, neuromodulation; Michael Phalen, EVP & president, medsurg; David Pierce, SVP & president, urology & pelvic health; Timothy Pratt, EVP, chief administrative officer, general counsel & secretary; Brad Sorenson, SVP, manufacturing & supply chain; Eric Thépaut, SVP & president, Europe;

Marlborough, Massachusetts